Prime Medicine, Inc. (PRME) Stock

Prime Medicine, Inc. (PRME) is a Healthcare stock trading at $3.38 (as of 2026-08-21), with a market capitalization of $583.39M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Understand Prime Medicine, Inc.: how it makes money

Prime Medicine develops genetic therapies using gene editing, delivering Prime Editors (a Prime Editor fusion protein plus a pegRNA) to drive targeted DNA edits, and it records collaboration revenue.

The profit model is collaboration-driven, because the company’s only revenue categories shown are collaboration revenues (including related-party collaborations), while the core platform is gene editing delivered through Prime Editors.

Revenue by segment (latest quarter)
Collab$0.0B
CollabRel$0.0B

Business quality (Weak): Early-stage biotechnology profile, with no reported revenue in the latest period and heavy operating losses, so near-term investment returns likely hinge on clinical and collaboration progress.

Bull case

  • Targeted gene editing design: Prime Editors combine a Prime Editor protein (a fusion between a Cas protein and a reverse transcriptase enzyme) with a pegRNA that targets the Prime Editor to a specific genomic location to enable the desired DNA edit.
  • Clinical-style efficacy and engraftment readouts reported: Reported endpoints include complete restoration of NADPH oxidase activity in neutrophils by day 15 (58 percent) and by day 30 (66 percent), and engraftment confirmation days of 14 (neutrophils) and 19 (platelets).

Bear case

  • No revenue in the latest reported quarter: For 2026-03-31, revenue is 0.0, and the segment revenue categories shown (collaboration revenue and collaboration revenue from related parties) are both 0.0.
  • Large operating loss: The operating margin for 2026-03-31 is -4961.2, which indicates significant ongoing expenses relative to revenue.
Valuation — source: SEC EDGAR (first-party)
Price$3.38
Market Cap$583.39M
Price / Book7.61
Price / Sales121.16
FCF Yield-54.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4.63M
Net Margin-4342.4%
Revenue Growth (YoY)55.3%
EPS Growth (YoY)-18.2%
FCF Growth (YoY)28.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.54 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderAlphabet Inc. ($57.64M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAllan Reine
Employees214
CountryUS
IPO Date2022-10-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Tectonic Therapeutic, Inc. (TECX)
  • Eikon Therapeutics, Inc. Common Stock (EIKN)
  • REGENXBIO Inc. (RGNX)
  • Zura Bio Limited (ZURA)
  • Artiva Biotherapeutics, Inc. (ARTV)
  • Cabaletta Bio, Inc. (CABA)
  • Kyverna Therapeutics, Inc. (KYTX)
  • C4 Therapeutics, Inc. (CCCC)
PRME earnings history · PRME institutional & insider holders · PRME KPIs & operating metrics · PRME financials · PRME investor presentations & press releases · PRME SEC filings · PRME peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.